Showing 3801-3810 of 5015 results for "".
- Psoriatic Disease Tied to Elevated APS Incidence: Studyhttps://practicaldermatology.com/news/psoriatic-disease-tied-to-elevated-aps-incidence-study/2483386/Data from a new cohort study has identified an increased risk of antiphospholipid syndrome (APS) in patients with psoriasis, particularly those with psoriatic arthritis (PsA). Researchers for the study matched 288,678 patients fro
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
- Skin Microbiome and Aging: Connected for the Long Haul?https://practicaldermatology.com/news/skin-microbiome-and-aging-connected-for-the-long-haul/2483286/The skin microbiome is not just a passive reflection of age, but in fact may be a key player in how skin ages and its ability to resist decline. During her presentation on the intersection of microbiomes and skin aging at the 2025 Science of Skin Summit in Austin, TX, Julia Oh, PhD, a prof
- Long-Term Data Support Safety of Upadacitinib in Women With AD Using OCPshttps://practicaldermatology.com/news/long-term-data-support-safety-of-upadacitinib-in-women-with-ad-using-ocps/2483285/Upadacitinib maintains a favorable benefit–risk profile in women with moderate-to-severe atopic dermatitis (AD), regardless of oral contraceptive pill (OCP) or hormone replacement therapy (HRT) use, according to long-term safety data presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) C
- Early Childhood Stress Tied to Psoriasis Riskhttps://practicaldermatology.com/news/early-childhood-stress-tied-to-psoriasis-risk/2483262/A prospective cohort study from Sweden suggests that early childhood stress, particularly disruptions in family structure, may increase the risk of developing psoriasis later in life. The research, published in the Journal of Investigative Dermatology
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://practicaldermatology.com/news/amarte-relaunches-ultra-veil-daily-spf-40/2483087/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat